FDA accepts BristolMyers Squibbs application for Sprycel for treating pediatric leukemia

July 20, 2019 | | Post a Comment

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Aug 30 2018Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental Biologics License Application (sBLA) for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The FDA action date is December 29, 2018.Related StoriesHeart failure drug could be effective in treating leukemiaNew Australian drug trial achieves remarkable results in patients with acute myeloid leukemiaCancer stem cells elude the body’s immune cells by deactivating danger detector”Sprycel was first established as an important treatment option for appropriate pediatric patients last year, when it was approved for the treatment of children with Ph+ chronic myeloid leukemia,” said Jeffrey Jackson, Ph.D., development lead, hematology, Bristol-Myers Squibb. “This latest milestone in Ph+ ALL reinforces our commitment to researching the potential of Sprycel in different types of pediatric leukemia and to providing this vulnerable population with access to potential new therapies.”The application is based on data from CA180-372 (NCT01460160), an ongoing Phase 2 trial evaluating the addition of Sprycel to a chemotherapy regimen modeled on a Berlin-Frankfurt-Munster high-risk backbone in pediatric patients with newly diagnosed Ph+ ALL. Source: https://www.bms.com/last_img



Want to say something? Post a comment

Your email address will not be published. Required fields are marked *